Estrogen esters (3)
Hormonal agents (3)
Androgen esters (2)
Estradiol esters (2)
Estradiol mustard (22966-79-6)
Estradiol mustard (developmental code name NSC-112259), also known as chlorphenacyl estradiol diester, as well as estradiol 3,17β-bis(4-(bis(2-chloroethyl)amino)phenyl)acetate, is a synthetic, steroidal estrogen and alkylating antineoplastic agent and a chlorphenacyl nitrogen mustard-coupled estrogen ester that was never marketed. It is selectively distributed into estrogen receptor (ER)-positive tissues such as ER-expressing tumors like those seen in breast and prostate cancers. For this reason, estradiol mustard and other cytostatic-linked estrogens like estramustine phosphate have reduced toxicity relative to non-linked nitrogen mustard alkylating antineoplastic agents.
LS-1727, also known as nandrolone 17β-N-(2-chloroethyl)-N-nitrosocarbamate, is a synthetic, injected anabolic–androgenic steroid (AAS) and a nitrosocarbamate ester of nandrolone (19-nortestosterone) that was developed as an alkylating antineoplastic agent but was never marketed.
Estromustine (developmental code name Leo 271 f), also known as estrone 17β-3-N-bis(2-chloroethyl)carbamate or estrone-cytostatic complex, is a major active metabolite of the cystotatic estrogen and nitrogen mustard alkylating antineoplastic agent estramustine phosphate, a drug used in the treatment of prostate cancer.
Phenestrol (developmental code name NSC-183736), or fenestrol, also known as hexestrol bis[4-[bis(2-chloroethyl)amino]phenylacetate, is a synthetic, nonsteroidal estrogen and alkylating antineoplastic agent (i.e., chemotherapy drug) and a chlorphenacyl nitrogen mustard ester of hexestrol that was developed in the early 1960s for the treatment of hormone-dependent tumors but was never marketed.